Os therapies granted end of phase 2 meeting by us fda for ost-her2 program in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma

New york--(business wire)--os therapies (nyse-a: ostx) (“os therapies” or “the company”), a clinical-stage immunotherapy and antibody drug conjugate (adc) biopharmaceutical company, today announced it was granted an end of phase 2 meeting by the united states food & drug administration (“fda”) to review the ost-her2 program in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. the company expects the meeting to occur in the third quarter of 2025. the en.
OST Ratings Summary
OST Quant Ranking